+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Schistosomiasis Pipeline Drugs and Companies, 2021- Phase, Mechanism of Action, Route, Licensing/Collaboration, Pre-clinical and Clinical Trials

  • PDF Icon


  • 70 Pages
  • November 2021
  • Region: Global
  • VPA Research
  • ID: 5463703
Schistosomiasis pipeline drugs and companies, 2021- Phase, Mechanism of Action, Route, Licensing/collaboration, pre-clinical and clinical trials

The global comprehensive report on “Schistosomiasis pipeline drugs and companies” presents key-decision makers with critical insights into Schistosomiasis pipeline data. It provides complete analysis on pipeline drugs detailing Phases, route of administration, mechanism of action, licensing and collaborations, clinical trial details including pre-clinical phase and clinical trials.

Schistosomiasis pipeline Drug Snapshot, 2021

The Schistosomiasis pipeline study analyzes and monitors the development landscape with the current status of each of the pipeline drugs under development for Schistosomiasis. In addition to recent status, overview of drugs is included in the study. Wide range of Schistosomiasis drug related details including of company, indication, country, current status, drug alternative names, originator, orphan drug status, fast track details and others are provided.

Schistosomiasis drug development pipeline by phase

The Schistosomiasis pipeline study monitors the progress of new drug programs and provides analysis of phases, covering drugs from discovery to launch including discovery stage, preclinical, phase 1, phase 2, phase 3, pre-registration and other phases. The drug development stage for all Schistosomiasis pipeline candidates is provided in the report enables you to understand timetable developments in Schistosomiasis therapeutic area.

Schistosomiasis pipeline drug Technology, Licensing and Collaboration Details

Details of technologies used for development of Schistosomiasis pipeline candidates, licensing and collaboration agreements, partnership and other announcements, regulatory approval and other details are included in the Schistosomiasis research study. Companies looking to partner with other players are also detailed in the report.

Schistosomiasis- mechanism of action of pipeline candidates

Schistosomiasis pipeline guide details the mechanism of action of each of the drug candidate under development. Further, leading types of mechanism of action (MoA) targeted by different Schistosomiasis companies are identified to support decision makers target the most potential drugs under development.

Further, route of administration including oral, topical, sub-cutaneous, IV, ophthalmic and others are provided to assist researchers to understand most sought and least sought route of Schistosomiasis drug administration.

Schistosomiasis Drugs- Preclinical and Clinical Trials

This chapter in Schistosomiasis preclinical and clinical trials assists in gaining clear understanding of the timetable developments in Schistosomiasis product area. Preclinical and clinical trial details of pipeline candidates for Schistosomiasis are detailed in the report. Details including participants, duration, companies, locations and others are provided for the trials.

Schistosomiasis companies and Profiles

Companies developing Schistosomiasis pipeline products are analyzed in the industry report, presenting details of business overview, location, and year of establishment, contacts, key employees, and a brief business profile.

Schistosomiasis Market Developments

The report presents the recent news and developments in the Schistosomiasis pipeline industry. Progress of candidates, mergers, acquisitions, asset transactions, licensing, collaborations, partnership and joint ventures, regulatory approvals, marketing and other relevant news and deals are discussed in the report.

Reasons to Buy

  • Make better-informed decisions based on the current status of each of the pipeline drug candidate
  • Identify new business opportunities by evaluating the progress of the Schistosomiasis R&D pipeline
  • Analyze the market and research segments based on a comprehensive analysis of Schistosomiasis pipeline drugs and clinical trials
  • Identify Schistosomiasis drug pipeline trends based on consistently delivered hands on pipeline and clinical trials information
  • Gain clear understanding of the Schistosomiasis drugs through our expert coverage and in-depth analysis of drugs, companies and market trends
  • Check the Schistosomiasis pipeline progress of target companies and key strategies of leading players
  • Gain real-time insights into the global Schistosomiasis pipeline news, developments and insights

Scope of the Report

  • Disease overview including Schistosomiasis symptoms, widely used treatment options, companies and other details are included
  • Schistosomiasis Pipeline Summary including the dominant phase type, number of drug candidates progressing to advanced phases, early stage pipeline candidates, leading companies, dominant route of mechanism and route of administration and other details are provided.
  • Schistosomiasis pipeline drug count by phase, company and mechanism of action
  • Schistosomiasis companies investing R&D resources in pipeline
  • Dominant Mechanism of Action
  • Most researched route of administration
  • For each pipeline candidate, drug, originator, co-developers, other companies, special status, phase, synonym, current status and other details are included
  • Clinical trial information for each Schistosomiasis pipeline candidate are provided including preclinical, phase 1, phase 2 and phase 3 details
  • Schistosomiasis companies including their business snapshot, business description and Schistosomiasis pipelines are included.
  • Recent Schistosomiasis market developments, pipeline news and deals are provided

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Executive Summary
2.1 Schistosomiasis Disease overview
2.2 Companies investing in Schistosomiasis industry
3 Schistosomiasis Pipeline Snapshot, 2021
3.1 Schistosomiasis Pipeline Drugs- Dominant phase type
3.2 Schistosomiasis pipeline Drugs- Leading Mechanism of Action
3.3 Schistosomiasis Pipeline Drugs- Widely researched Route of Administration
3.4 Schistosomiasis Pipeline- New Molecular Entity
3.5 Schistosomiasis pipeline- Companies, Universities and Institutes
4. Schistosomiasis Drug Profiles
4.1 Current Status of Schistosomiasis Drug Candidates, 2021
4.2 Schistosomiasis Drugs in Development- Originator/Licensor
4.3 Schistosomiasis Drugs in Development- Route of Administration
4.4 Schistosomiasis Drugs in Development- New Molecular Entity (NME)
5. Schistosomiasis Clinical Trials
5.1 Preclinical Trial details
5.2 Phase 1 Clinical Trial Details
5.3 Phase 2 Clinical Trial Details
5.4 Phase 3 Clinical Trial Details
6. Schistosomiasis Companies and Universities
6.1 Leading Schistosomiasis companies researching in drug development
6.2 Leading Schistosomiasis Universities/Institutes investing in drug development
7. Schistosomiasis News and Deals
7.1 Recent Schistosomiasis Market Developments
7.2 Pipeline Drug News Updates
7.3 Pipeline Company updates
8. Appendix
8.1 Sources and Research Methodology
8.2 Online Database
8.3 Primary and Secondary Methodology
8.4 Customization options
8.5 Contact